Heterocyclic mGlu2/3 Receptor Agonists
Journal of Medicinal Chemistry, 2007, Vol. 50, No. 2 239
(21) Moghaddam, B.; Adams, B. Reversal of phencyclidine effects by a
group II metabotropic glutamate receptor agonist in rats. Science
1998, 281, 1349-1352.
(22) Cartmell, J.; Monn, J. A.; Schoepp, D. D. The metabotropic glutamate
2/3 receptor agonists LY354740 and LY379268 attenuate phencyc-
lidine versus d-amphetamine motor behaviors in rats. J. Pharmacol.
Exp. Ther. 1999, 29, 161-170.
(23) Spooren, W. P. J. M.; Gasparini, F.; van der Putten, H.; Koller, M.;
Nakanishi, S.; Kuhn, R. Lack of effect of LY314582 (a group 2
metabotropic glutamate receptor agonist) on phencyclidine-induced
locomotor activity in metabotropic glutamate receptor 2 knockout
mice. Eur. J. Pharmacol. 2000, 397, R1-R2.
(24) Klodzinska, A.; Chojnacka-Wojcik, E.; Pilc, A. Selective group II
glutamate metabotropic receptor agonist LY354740 attenuates pen-
tetrazole- and picrotoxin-induced seizures. Pol. J. Pharmacol. 1999,
51, 543-545.
(25) Klodzinska, A.; Bijak, M.; Chojnacka-Wojcik, E.; Kroczka, B.;
Swiader, M.; Czuczwar, S. J.; Pilc, A. Roles of group II metabotropic
glutamate receptors in modulation of seizure activity. Naunyn-
Scmiedeberg’s Arch. Pharmacol. 2000, 361, 283-288.
(26) Konieczny, J.; Ossowska, K.; Wolfarth, S.; Pilc, A. LY354740, a
group II metabotropic glutamate receptor agonist with potential
antiparkinsonian properties in rats. Nauyn-Schmiedeberg’s Arch.
Pharmacol. 1998, 358, 500-502.
(27) Wolfarth, S.; Konieczny, J.; Lorenc-Koci, E.; Ossowska, K.; Pilc,
A. The role of metabotropic glutmate receptor (mGluR) ligands in
parkinsonian muscle rigidity. Amino Acids 2000, 19, 95-101.
(28) Simmons, R. M. A.; Webster, A. A.; Kaira, A. B; Iyengar, S. Group
II mGluR receptor agonists are effective in persistent and neuropathic
pain models in rats. Pharmacol. Biochem. BehaV. 2002, 73, 419-
427.
(29) Bond, A.; O’Neill, M. J.; Hicks, C. A.; Monn, J. A.; Lodge, D.
Neuroprotective effects of a systemically active group II metabotropic
glutamate receptor agonist LY354740 in a gerbil model of global
ischemia. NeuroReport 1998, 9, 1191-1193.
(30) Kingston, A. E.; O’Neill, M. J.; Lam, A.; Bales, K. R.; Monn, J. A.;
Schoepp, D. D. Neuroprotection by metabotropic glutamate receptor
agonists: LY354740, LY379268 and LY389795. Eur. J. Pharmacol.
1999, 377, 155-165.
(31) Kingston, A. E.; O’Neill, M. J.; Bond, A.; Bruno, V.; Battaglia, G.;
Nicoletti, F.; Harris, J. R.; Clark, B. P.; Monn, J. A.; Lodge, D.;
Schoepp, D. D. Neuroprotective actions of novel and potent ligands
of group I and group II metabotropic glutamate receptors. Ann. N.Y.
Acad. Sci. 1999, 890, 438-449.
(32) Allen, J. W.; Ivanova, S. A.; Fan, L.; Espey, M. G.; Basile, A. S.;
Faden, A. I. Group II metabotropic glutamate receptor activation
attenuates traumatic neuronal injury and improves neurological
recovery after traumatic brain injury. J. Pharmacol. Exp. Ther. 1999,
290, 112-120.
(33) Dominguez, C.; Prieto, L.; Valli, M. J.; Massey, S. M.; Bures, M.;
Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.; Schoepp,
D. D.; Monn, J. A. Methyl substitution of 2-aminobicyclo[3.1.0]-
hexane-2,6-dicarboxylate (LY354740) determines functional activity
at metabotropic glutamate receptors: identification of a subtype
selective mGlu2 receptor agonist. J. Med. Chem. 2005, 48, 3605-
3612.
(34) The absolute stereochemistry of (-)-3 was determined by single
crystal X-ray of the R-2-phenylglycinol salt of hydantoin precursor
shown below. The preparation of this intermediate and its conversion
to (-)-3 are detailed in reference 14. The X-ray structure and
coordinates have been filed with the Cambridge Crystallographic
Database and are available as Supporting Information.
References
(1) Hollmann, M.; Heinemann, S. Cloned glutamate receptors. Annu.
ReV. Neurosci. 1994, 17, 31-108.
(2) Nakanishi, S.; Masu, M. Molecular Diversity and functions of
glutamate receptors. Annu. ReV. Biophys. Biomol. Struct. 1994, 23,
319-348.
(3) Pellicciari, R.; Constantino, G. Metabotropic G-protein-coupled
glutamate receptors as therapeutic targets. Curr. Opin. Chem. Biol.
1999, 3, 433-440.
(4) Neugebauer, V. Metabotropic glutamate receptors: Novel targets for
pain relief. Expert ReV. Neurother. 2001, 1, 207-224.
(5) Salt, T. E. Metabotropic glutamate (mGlu) receptors and nociceptive
processing. Drug DeV. Res. 2002, 54, 129-139.
(6) Marino, M. J.; Conn, J. P. Modulation of the basal ganglia by
metabotropic glutamate receptors: Potential for novel therapeutics.
Curr. Drug Targets 2002, 1, 239-250.
(7) Doherty, J.; Dingledine, R. The roles of metabotropic glutamate
receptors in seizures and epilepsy. Curr. Drug Targets 2002, 1, 251-
260.
(8) Chavez-Noriega, L. E.; Schaffhauser, H.; Campbell, U. C. Metabo-
tropic glutamate receptors: potential drug targets for the treatment
of schizophrenia. Curr. Drug Targets 2002, 1, 261-281.
(9) Wolfarth, S.; Konieczny, J.; Lorenc-Koci, E.; Ossowska, K.; Pilc,
A. The role of metabotropic glutamate receptor (mGluR) ligands in
parkinsonian muscle rigidity. Amino Acids 2000, 19, 95-101.
(10) Bruno, V.; Battaglia, G.; Copani, A.; D’Onofrio, M.; Di Iorio, P.;
De Blasi, A.; Melchiorri, D.; Flor, P. J.; Nicoletti, F. Metabotropic
glutamate receptor subtypes as targets for neuroprotective drugs. J.
Cereb. Blood Flow Metab. 2001, 21, 1013-1033.
(11) Schoepp, D. D.; Johnson, B. G.; Wright, R. A.; Salhoff, C. R.; Mayne,
N. G.; Wu, S.; Cockerham, S. L.; Burnett, J. P.; Belagaje, R.;
Bleakman, D.; Monn, J. A. LY354740 is a potent and highly selective
group II metabotropic glutamate receptor agonist in cells expressing
human glutamate receptors. Neuropharmacology 1997, 36, 1-11.
(12) Monn, J. A.; Valli, M. J.; Massey, S. M.; Wright, R. A.; Salhoff, C.
R.; Johnson, B. G.; Howe, T.; Alt, C. A.; Rhodes, G. A.; Robey, R.
L.; Griffey, K. R.; Tizzano, J. P.; Kallman, M. J.; Helton, D. R.;
Schoepp, D. D. Design, synthesis, and pharmacological characteriza-
tion of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
(LY354740): A potent, selective, and orally active group 2 metabo-
tropic glutamate receptor agonist possessing anticonvulsant and
anxiolytic properties. J. Med. Chem. 1997, 40, 528-537.
(13) Schoepp, D. D.; Monn, J. A.; Marek, G. J.; Aghajanian, G.;
Moghaddam, B. LY354740: A systemically active mGlu2/mGlu3
receptor agonist. CNS Drug ReV. 1999, 5, 1-12.
(14) Monn, J. A.; Valli, M. J.; Massey, S. M.; Hansen, M. M.; Kress, T.
J.; Wepsiec, J. P.; Harkness, A. R.; Grutsch, J. L., Jr.; Wright, R.
A.; Johnson, B. G.; Andis, S. L.; Kingston, A. E.; Tomlinson, R.;
Lewis, R.; Griffey, K. R.; Tizzano, J. P.; Schoepp, D. D. Synthesis,
pharmacological characterization, and molecular modeling of het-
erobicyclic amino acids related to LY354740: Identification of two
new potent, selective, and systemically active agonists for group II
metabotropic glutamate receptors. J. Med. Chem. 1999, 42, 1027-
1040.
(15) Helton, D. R.; Tizzano, J. P.; Monn, J. A.; Schoepp, D. D.; Kallman,
M. J. Anxiolytic and side-effect profile of LY354740: A potent,
highly selective, orally active agonist for group II metabotropic
glutamate receptors. J. Pharmacol. Exp. Ther. 1998, 284, 651-660.
(16) Klodzinska, A.; Chojnacka-Wojcik, E.; Paiucha, A.; Branski, P.;
Popik, P.; Pilc, A. Potential anti-anxiety, anti-addictive effects of
LY354740, a selective group II glutamate metabotropic receptors
agonist in animal models. Neuropharmacology 1999, 38, 1831-1839.
(17) Ferris, P.; Seward, E.; Dawson, G. R. Interactions between LY354740,
a group II metabotropic agonist and the GABA-A-benzodiazepine
receptor complex in the rat elevated plus-maze. J. Psychopharmacol.
2001, 15, 76-82.
(18) Tatarczynska, E.; Klodzinska, A.; Kroczka, B.; Chojnacka-Wojcik,
E.; Pilc., A. The antianxiety-like effects of antagonists of group I
and agonists of group II and III metabotropic glutamate receptors
after intrahippocampal administration. Psychopharmacology 2001,
158, 94-99.
(19) Spooren, W. P. J. M.; Schoeffter, P.; Gasparini, F.; Kuhn, R.; Gentsch,
C. Pharmacological and endocrinological characterization of stress-
induced hyperthermia in singly housed mice using classical and
candidate anxiolytics (LY314582, MPEP and NKP608). Eur. J.
Pharmacol. 2002, 435, 161-170.
(20) Tizzano, J. P.; Griffey, K. I.; Schoepp, D. D. The anxiolytic action
of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle
model in rats is mechanistically distinct from diazepam. Pharmacol.,
Biochem. BehaV. 2002, 73, 367-374.
(35) The X-ray structure and coordinates for (-)-7 and (+)-11 have been
filed with the Cambridge Crystallographic Database. Coordinate data
for each are available as Supporting Information.
(36) More extensive pharmacological and pharmacokinetic characterization
of (+)-12 will be reported in the following: Rorick-Kehn, L.;
Johnson, B. G.; Burkey, J. L.; Wright, R. A.; Calligaro, D. O.; Marek,
G. J.; Nisenbaum, E. S.; Catlow, J. T.; Kingston, A. E.; Monn, J.
A.; McKinzie, D. L.; Schoepp, D. D. Pharmacological and pharma-
cokinetic properties of a structurally-novel, potent, selective mGlu2/3
receptor agonist: In Vitro characterization of LY404039. J. Phar-
macol. Exp. Ther. 2006, accepted for publication.